<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902018000300236</article-id>
<article-id pub-id-type="doi">10.29262/ram.v65i3.369</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desensibilización a alopurinol en paciente con gota tofácea]]></article-title>
<article-title xml:lang="en"><![CDATA[De-sensitization to allopurinol in a patient with tophi gout]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Rocha]]></surname>
<given-names><![CDATA[Eunice Giselle]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Montoya]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Pesina]]></surname>
<given-names><![CDATA[Alberto Hernán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Mireles]]></surname>
<given-names><![CDATA[Karen Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Alergia e Inmunología Clínica  ]]></institution>
<addr-line><![CDATA[ San Luis Potosí]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General Río Verde  ]]></institution>
<addr-line><![CDATA[Río Verde San Luis Potosí]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Alergia e Inmunología Clínica  ]]></institution>
<addr-line><![CDATA[ Nuevo León]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<numero>3</numero>
<fpage>316</fpage>
<lpage>320</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902018000300236&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902018000300236&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902018000300236&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El alopurinol es un inhibidor de la xantinooxidasa usado en el tratamiento de pacientes con gota. Aproximadamente 2 % de los pacientes son afectados por reacciones adversas a dicho fármaco. La severidad varía de erupciones cutáneas leves a reacciones graves hasta en 0.4 % de los casos. La desensibilización se lleva a cabo incrementando paulatinamente la dosis del fármaco.  Reporte de caso Hombre de 30 años con diagnóstico de hipercolesterolemia e hipertrigliceridemia tratadas con bezafi brato y pravastatina, hipertensión arterial sistémica tratada con losartán e hiperuricemia con gota de 10 años de diagnóstico. Los tofos se encontraban en articulaciones metacarpofalángicas y codos. Se inició tratamiento con 300 mg diarios de alopurinol, a las dos semanas el paciente presentó eritema facial con prurito y lesiones maculopapulares en región malar una hora después de la ingesta del medicamento. Se inició protocolo ambulatorio de desensibilización a dicho fármaco comenzando con 5 mg, con incremento gradual de la dosis cada cuatro o cinco días por 59 días, hasta llegar a la dosis de mantenimiento deseada (300 mg).  Conclusiones: La experiencia muestra que la desensibilización a alopurinol es una alternativa segura cuando existe hipersensibilidad y necesidad de tratamiento con este fármaco.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Allopurinol is a xanthine oxidase inhibitor used in the treatment of patients with gout. Approximately 2% of patients are aff ected by adverse reactions to this drug. Severity ranges from mild rashes to severe reactions in up to 0.4% of cases. De-sensitization is carried out by administering increasing doses of the drug.  Case report: Thirty-year old man diagnosed with hypercholesterolemia and hypertriglyceridemia treated with bezafi brate and pravastatin, systemic arterial hypertension treated with losartan and a 10-year history of hyperuricemia with gout. Tophi were found in metacarpophalangeal joints and elbows. Treatment was started with allopurinol 300 mg/day. Two weeks later, he experienced facial erythema with itching and maculopapular lesions on the malar region 1 hour after the medication was ingested. An outpatient drug de-sensitization protocol was initiated, starting with 5 mg, and with gradual dose increases every 4 to 5 days for 59 days until the desired maintenance dose (300 mg) was reached.  Conclusions: Experience shows that de-sensitization to allopurinol is a safe alternative when there is hypersensitivity and treatment with this drug is required.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Gota tofácea]]></kwd>
<kwd lng="es"><![CDATA[Ácido úrico]]></kwd>
<kwd lng="es"><![CDATA[Desensibilización a alopurinol]]></kwd>
<kwd lng="en"><![CDATA[Tophi gout]]></kwd>
<kwd lng="en"><![CDATA[Uric acid]]></kwd>
<kwd lng="en"><![CDATA[De-sensitization to allopurinol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanna]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization to allopurinol in a patient with previous failed desensitization]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1999</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1180-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mclnnes]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Jick]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute adverse reactions attributed to allopurinol in hospitalized patients]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>1981</year>
<numero>3</numero>
<issue>3</issue>
<page-range>245-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fam]]></surname>
<given-names><![CDATA[AG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient]]></article-title>
<source><![CDATA[Curr Rheumatol Rep.]]></source>
<year>2001</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-35</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calogiuri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Netis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Di-Leo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Foti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Butani]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules]]></article-title>
<source><![CDATA[Inflamm Allergy Drug Targets.]]></source>
<year>2013</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-28</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fam]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Dunne]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Iazzetta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[TW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of desensitization to allopurinol following cutaneous reactions]]></article-title>
<source><![CDATA[Arthitis Rheum.]]></source>
<year>2001</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>231-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-Ortega]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trindade]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Llamazares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castellano-Bravo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cimarra-Álvarez-Lovell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cócera]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipersensibilidad al alopurinol: Eficacia de un protocolo de desensibilización en tres casos]]></article-title>
<source><![CDATA[An Med Interna.]]></source>
<year>2001</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toker]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Tvito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ashkenazi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ganzel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tal]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid oral allopurinol desensitization in a patient with chronic myeloid leukemia]]></article-title>
<source><![CDATA[Isr Med Assoc J.]]></source>
<year>2014</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>461-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rios]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kalesnikoff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Galli]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2013</year>
<volume>132</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>922-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Caiado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allopurinol desensitization: a fast or slow protocol?]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol.]]></source>
<year>2015</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>295-315</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calogiuri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nettis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Di Leo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Foti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Butani]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules]]></article-title>
<source><![CDATA[Inflamm Allergy Drug Targets.]]></source>
<year>2013</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-28</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyrier]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization in a patient with chronic renal disease and severe allergy to allopurinol.]]></article-title>
<source><![CDATA[Br Med J.]]></source>
<year>1976</year>
<volume>2</volume>
<numero>6033</numero>
<issue>6033</issue>
<page-range>458</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walz-LeBlanc]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[MacFadden]]></surname>
<given-names><![CDATA[DK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization]]></article-title>
<source><![CDATA[Arthitis Rheum.]]></source>
<year>1991</year>
<volume>34</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1329-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
